Skip to main content
Signal8

Karyopharm Therapeutics Inc. (KPTIQ)

Sector: Pharmaceutical Preparations

Karyopharm Therapeutics, Inc. logo

Karyopharm Therapeutics, Inc.

OTC:KPTIQOTC (suspended from Nasdaq on Nov 11, 2026)Healthcare
+36.36%$0.0390
Mkt Cap$885K
EV-
Float21.62M
O/S22.68M
VOL2.25M sh
$ Vol$79K
RVOL0.70×
Inst Own76.4%
Net Cash/Sh-
Dilution
Karyopharm Therapeutics, Inc. logoOTC:KPTIQ$0.0390+36.36%
Phase Distribution
37 lead-sponsored trials·8 active·12 completed
Phase 15
Phase 1/27
Phase 218
Phase 2/32
Phase 34
Not applicable1
(58 more as collaborator)
Status Overview
Recruiting3
Active, not recruiting5
Completed12
Stopped16
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

    Selinexor, Bortezomib

    Multiple Myeloma

    Enrollment
    402
    Start
    May 2017
    Primary Completion
    Feb 2020
    Completion
    May 2022
    NCT03110562
  • Phase 3
    Completed

    Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

    Selinexor, Matching placebo for selinexor

    Endometrial Cancer

    Enrollment
    263
    Start
    Jan 2018
    Primary Completion
    Jan 2022
    Completion
    Apr 2025
    NCT03555422
  • Phase 3
    Active, not recruiting

    Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

    Selinexor, Selinexor

    Myelofibrosis

    Enrollment
    353
    Start
    Mar 2021
    Primary Completion
    Feb 2026
    Completion
    Mar 2028est.
    NCT04562389
  • Phase 3
    Active, not recruiting

    Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

    Selinexor, Matching Placebo for selinexor

    Endometrial Cancer

    Enrollment
    257
    Start
    Apr 2023
    Primary Completion
    May 2026
    Completion
    Jan 2028est.
    NCT05611931
  • Phase 2/3
    Completed

    Selinexor in Advanced Liposarcoma

    Selinexor, Placebo

    Dedifferentiated Liposarcoma

    Enrollment
    342
    Start
    Jan 2016
    Primary Completion
    Oct 2020
    Completion
    Oct 2021
    NCT02606461
  • Phase 2/3
    Active, not recruiting

    A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    Selinexor (combination therapy), Selinexor (combination therapy)

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    Enrollment
    501
    Start
    Sep 2020
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT04442022
  • Phase 2
    Terminated

    Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

    Selinexor

    Glioblastoma, Glioma

    Enrollment
    76
    Start
    Mar 2014
    Primary Completion
    Jan 2020
    Completion
    Jan 2020
    NCT01986348
  • Phase 2
    Completed

    Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies

    Selinexor

    Ovarian Carcinoma, Endometrial Carcinoma +1

    Enrollment
    116
    Start
    Apr 2014
    Primary Completion
    Jan 2017
    Completion
    Mar 2017
    NCT02025985
  • Phase 2
    Completed

    Selinexor (KPT-330) in Older Patients With Relapsed AML

    Selinexor, Hydroxyurea

    Acute Myeloid Leukemia (AML)

    Enrollment
    317
    Start
    Mar 2014
    Primary Completion
    Jan 2018
    Completion
    Jan 2018
    NCT02088541
  • Phase 2
    Terminated

    Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

    selinexor

    Richter's Transformation

    Enrollment
    27
    Start
    Nov 2014
    Primary Completion
    Aug 2016
    Completion
    Aug 2016
    NCT02138786
  • Phase 2
    Terminated

    SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

    Selinexor

    Prostate Cancer

    Enrollment
    20
    Start
    May 2014
    Primary Completion
    Apr 2016
    Completion
    Apr 2016
    NCT02146833
  • Phase 2
    Terminated

    Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

    Selinexor (KPT-330)

    Squamous Cell Carcinoma

    Enrollment
    45
    Start
    Sep 2014
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT02213133
  • Phase 2
    Active, not recruiting

    Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Selinexor, Selinexor

    Diffuse Large B-cell Lymphoma

    Enrollment
    244
    Start
    Nov 2014
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT02227251
  • Phase 2
    Terminated

    Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

    Selinexor

    Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)

    Enrollment
    16
    Start
    Feb 2015
    Primary Completion
    Jan 2016
    Completion
    Feb 2016
    NCT02314247
  • Phase 2
    Completed

    Selinexor Treatment of Refractory Myeloma

    Selinexor, Dexamethasone

    Multiple Myeloma

    Enrollment
    202
    Start
    May 2015
    Primary Completion
    Jul 2019
    Completion
    Jul 2019
    NCT02336815
  • Phase 2
    Withdrawn

    Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients

    Selinexor

    Myelodysplastic Syndrome

    Enrollment
    0
    Start
    Nov 2015
    Primary Completion
    Dec 2017est.
    Completion
    May 2019est.
    NCT02431351
  • Phase 2
    Withdrawn

    Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

    Selinexor, Placebo (for selinexor)

    Multiple Myeloma

    Enrollment
    0
    Start
    Dec 2015
    Primary Completion
    Jun 2017est.
    Completion
    Jun 2018est.
    NCT02628704
  • Phase 2
    Completed

    Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

    Selinexor

    Coronavirus Infection

    Enrollment
    190
    Start
    Apr 2020
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT04349098
  • Phase 2
    Withdrawn

    Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

    Selinexor

    Coronavirus Infection

    Enrollment
    0
    Start
    Apr 2020
    Primary Completion
    Aug 2020
    Completion
    Aug 2020
    NCT04355676
  • Phase 2
    Recruiting

    A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

    Selinexor, Dexamethasone

    Multiple Myeloma, Refractory

    Enrollment
    127
    Start
    Jul 2020
    Primary Completion
    Jan 2028est.
    Completion
    Jan 2028est.
    NCT04414475
  • Phase 2
    Active, not recruiting

    A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

    Selinexor

    Myelofibrosis

    Enrollment
    112
    Start
    Mar 2021
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2026est.
    NCT04562870
  • Phase 2
    Terminated

    Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

    Selinexor, Pembrolizumab

    Locally Advanced Unresectable or Metastatic Melanoma

    Enrollment
    15
    Start
    May 2021
    Primary Completion
    Sep 2023
    Completion
    Sep 2023
    NCT04768881
  • Phase 2
    Terminated

    A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

    Selinexor, Pembrolizumab

    Metastatic Colorectal Cancer

    Enrollment
    13
    Start
    Jun 2021
    Primary Completion
    Jun 2022
    Completion
    Jun 2022
    NCT04854434
  • Phase 2
    Recruiting

    A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

    Selinexor 60 mg, Selinexor 40 mg

    Myelofibrosis, Moderate Thrombocytopenia +1

    Enrollment
    58
    Start
    Apr 2024
    Primary Completion
    Jun 2027est.
    Completion
    Oct 2028est.
    NCT05980806
  • Phase 1/2
    Recruiting

    Selinexor and Backbone Treatments of Multiple Myeloma Patients

    Selinexor, Dexamethasone

    Multiple Myeloma

    Enrollment
    300
    Start
    Oct 2015
    Primary Completion
    Apr 2027est.
    Completion
    Apr 2027est.
    NCT02343042

1-25 of 37